Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $33M (up 1471.6% year over year) with net income of −$51M.
Q3 2025 key financials · XBRL
- Revenue
- $33M
- +1471.6% YoY · +106.8% QoQ
- Net income
- −$51M
- −167.4% YoY · −14.0% QoQ
- Operating margin
- -163.7%
- EPS (diluted)
- −$0.52
- −173.7% YoY · −15.6% QoQ
Source: XBRL data from the ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 10-Q on SEC EDGAR. USD.
ARS Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin percentages disclosed in provided text
- Near-term focus on neffy commercialization, regulatory reviews, market acceptance, reimbursement, competition, and funding needs
Risk Factors
- Newly added legal risk: Lupin’s August 2025 Paragraph IV notice challenging eight Orange Book patents covering neffy 2 mg
- Regulatory risk: neffy lacks U.S. non-patent exclusivity, increasing exposure to generic competition under the 505(b)(2) pathway
- Operational risk: U.S. commercialization depends on sales-force execution and ALK co-promotion to up to 9,000 prescribers
- Market risk: neffy faces established injectable competitors including EpiPen, Auvi-Q, Adrenaclick, and Symjepi
- Commercial risk: inadequate third-party coverage or reimbursement could limit patient adoption and pricing realization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARS Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.